<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Diagn Pathol</journal-id>
      <journal-title-group>
        <journal-title>Diagnostic Pathology</journal-title>
      </journal-title-group>
      <issn pub-type="epub">1746-1596</issn>
      <publisher>
        <publisher-name>BioMed Central</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">22333190</article-id>
      <article-id pub-id-type="pmc">3298797</article-id>
      <article-id pub-id-type="publisher-id">1746-1596-7-16</article-id>
      <article-id pub-id-type="doi">10.1186/1746-1596-7-16</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>CD5-positive marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT) of the lung</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" corresp="yes" id="A1">
          <name>
            <surname>Terada</surname>
            <given-names>Tadashi</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>piyo0111jp@yahoo.co.jp</email>
        </contrib>
      </contrib-group>
      <aff id="I1"><label>1</label>Department of Pathology, Shizuoka City Shimizu Hospital, Shizuoka, Japan</aff>
      <pub-date pub-type="collection">
        <year>2012</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>14</day>
        <month>2</month>
        <year>2012</year>
      </pub-date>
      <volume>7</volume>
      <fpage>16</fpage>
      <lpage>16</lpage>
      <history>
        <date date-type="received">
          <day>20</day>
          <month>12</month>
          <year>2011</year>
        </date>
        <date date-type="accepted">
          <day>14</day>
          <month>2</month>
          <year>2012</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>Copyright &#xA9;2012 Terada; licensee BioMed Central Ltd.</copyright-statement>
        <copyright-year>2012</copyright-year>
        <copyright-holder>Terada; licensee BioMed Central Ltd.</copyright-holder>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0">
          <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0">http://creativecommons.org/licenses/by/2.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
        </license>
      </permissions>
      <self-uri xlink:href="http://www.diagnosticpathology.org/content/7/1/16"/>
      <abstract>
        <p>CD5-positive marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT) of the lung is very rare. An 82-year-old Japanese woman was found to have an abnormal lung shadow on chest X-ray photography, and was admitted to our hospital. Imaging modalities including X-ray photography, computed tomography, and magnetic resonance imaging showed a small (2 &#xD7; 1 &#xD7; 1 cm) opacity of the right upper lobe. Transbronchial lung biopsy was performed. It showed severe proliferation of small lymphocytes. The small lymphocytes were centrocytes-like, and minor plasma cell differentiation was recognized. Lymphoepithelial lesions were scattered. Immunohistochemically, the tumor cells were positive for CD5, CD20, CD43, CD45, CD79&#x3B1;, bcl-2, and &#x3BA;-chain, but negative for CD2, CD3, CD10, CD21, CD23, CD35, CD45RO, CD56, IgA, IgG, IgM, IgD, &#x3BB;-chain, TdT, and cyclin D1. The Ki-67 labeling was 10%. CD3-positive and CD45RO-positive inflammatory T-cells were scattered in small amount. The pathological diagnosis was CD5-positive marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT) of the lung. The patient was treated with chemotherapy (CHOP: cyclophosphamide, hydroxydaunorbicin, vincristine, and predonisone), and the lung tumor disappeared. The patient is now free of the lymphoma 10 years after the first manifestation.</p>
        <sec>
          <title>Virtual slides</title>
          <p>The virtual slide(s) for this article can be found here:</p>
          <p>
            <ext-link ext-link-type="uri" xlink:href="http://www.diagnosticpathology.diagnomx.eu/vs/1541653085652296">http://www.diagnosticpathology.diagnomx.eu/vs/1541653085652296</ext-link>
          </p>
        </sec>
      </abstract>
      <kwd-group>
        <kwd>Lymphoma</kwd>
        <kwd>lung</kwd>
        <kwd>histopathology</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec>
      <title>Introduction</title>
      <p>Malignant lymphoma of the lung is very rare [<xref ref-type="bibr" rid="B1">1</xref>]. Although any types of malignant lymphomas can occur in the lung, approximately 70-90% of the pulmonary lymphoma is marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT) of the lung [<xref ref-type="bibr" rid="B1">1</xref>]. Pulmonary lymphomas accounted for only 0.5% of all pulmonary neoplasms [<xref ref-type="bibr" rid="B1">1</xref>]. Patients with marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT) (abbreviated hereafter as MALT lymphoma) of the lung tend to be in their fifth, sixth, or seventh decades, with a slight male preponderance [<xref ref-type="bibr" rid="B1">1</xref>]. Etiologically, pulmonary MALT lymphoma is thought to arise in acquired MALT secondary to inflammatory or autoimmune process. The prognosis of pulmonary MALT lymphoma is relatively good when surgical resection is possible, while it may be worse in surgically-unresectable cases [<xref ref-type="bibr" rid="B1">1</xref>]. The 5-year survival of pulmonary MALT lymphoma is 84-94% [<xref ref-type="bibr" rid="B1">1</xref>]. Pulmonary MALT lymphoma progresses into diffuse large B-cell lymphoma in a small percentage, as is the case with MALT lymphoma of other organs. Other relatively common lymphomas and related diseases of the lung are diffuse large B-cell lymphoma, lymphomatoid granulomatosis, and Langerhans cell histiocytosis [<xref ref-type="bibr" rid="B1">1</xref>]. Histopathologically, pulmonary MALT lymphoma is an extranodal marginal zone lymphoma comprising morphologically of heterogeneous small B-cells, monocytoid cells, small lymphocytes, and scattered immunoblasts-like and centroblasts-like cells. There is a plasma cell differentiation in a proportion of cases. The neoplastic cells typically infiltrate into the bronchial mucosal epithelial cells, creating lymphoepithelial lesions [<xref ref-type="bibr" rid="B1">1</xref>].</p>
      <p>Most of MALT lymphoma is negative for CD5 [<xref ref-type="bibr" rid="B2">2</xref>]. However, there are a few reports of CD5-positive MALT lymphoma of the lung and other organs [<xref ref-type="bibr" rid="B3">3</xref>-<xref ref-type="bibr" rid="B13">13</xref>]. The CD5 positivity in MALT lymphoma made the diagnosis difficult, and many differential diagnoses should be considered. The significance, mechanism, and biological behaviors of CD5-positive MALT lymphoma are unknown [<xref ref-type="bibr" rid="B3">3</xref>-<xref ref-type="bibr" rid="B13">13</xref>]. The author herein reports the case of a CD5-positive pulmonary MALT lymphoma with good prognosis.</p>
    </sec>
    <sec>
      <title>Case report</title>
      <p>An 82-year-old Japanese woman was found to have abnormal lung shadow on chest X-ray photography at a private hospital. She was referred to our hospital for scrutiny. Imaging modalities including X-ray photography, computed tomography and magnetic resonance imaging showed a small (2 &#xD7; 1 &#xD7; 1 cm) opacity of right upper lobe. Abnormal blood laboratory data included mild leukocytosis (9.5 &#xD7; 10<sup>9 </sup>/L; normal 3.5-9.0 &#xD7; 10<sup>9</sup>/L), anemia (367 x10<sup>10 </sup>/L; normal, 370-480 &#xD7; 10<sup>10</sup>/L; hemoglobin 9.5 g/dl, normal 11 g/dl-16 g/dl), decreased total protein (63 g/L; normal 65-92 g/L), low zinc turbidity test (2.3 U; normal 4.0-12.0 U), and increased blood uria nitrogen (2.4 &#x3BC;mol/L; normal 2.9-8.9 &#x3BC;mol/L). The white blood cell compartment was as follows: basophils 1%, band neutrophils 2% (low), segmented neutrophils 84% (high), and lymphocytes 11% (low). Eosinophils and precursor cells were not recognized. Other data were normal. There was no M-protein. No hyper-gamma-globulinemia was noted. Examination of serum immunoglobulin components was not performed. Transbronchial lung biopsy (TBLB) was performed. The TBLB specimens consisted of several fragments. They are fragments of the proliferated lymphocytes (Figure <xref ref-type="fig" rid="F1">1A</xref>). The TBLB showed severe proliferation of small lymphocytes with scattered small centroblast-like cells (Figure <xref ref-type="fig" rid="F1">1B</xref>). The lymphocytes were centrocytes-like, and minor plasma cell differentiation was recognized (Figure <xref ref-type="fig" rid="F1">1B</xref>). Lymphoepithelial lesions were scattered (Figure <xref ref-type="fig" rid="F1">1B</xref>), and they were highlighted by cytokeratin immunostaining (Figure <xref ref-type="fig" rid="F1">1C</xref>). No follicular structures were found. No findings of Burkitt lymphoma were recognized.</p>
      <fig id="F1" position="float">
        <label>Figure 1</label>
        <caption>
          <p><bold>Histological features</bold>. A: Diffuse atypical lymphoid cell proliferation is seen. HE, &#xD7;100. B: The atypical cells are small lymphoid cells with hyperchromatic nuclei. Lymphoepithelial lesions are seen. HE, &#xD7; 400. C: The lymphoepithelial lesions are clearly accentuated by cytokeratin immunostaining. AE1/3 immunostaining, &#xD7;200.</p>
        </caption>
        <graphic xlink:href="1746-1596-7-16-1"/>
      </fig>
      <p>An immunohistochemical study was performed with the use of Dako's EnVision method (Dako Corp, Carpinteria, CA), as previously described [<xref ref-type="bibr" rid="B14">14</xref>-<xref ref-type="bibr" rid="B16">16</xref>].</p>
      <p>Each immunostaing was pretreated by microwave oven heating for 10 minutes. The antibodies, clones, and dilution used were as follows: CD2 (Dako, MT910, 1:100), CD3 (Dako, F7.2.38, 1:25), CD5 (Dako, CD5/54/F6, 1:50), CD10 (Novocastra, New Castle Upon Tyne, UK, NCL-CD10-270, 1:100), CD20 (Dako, L26, 1:100), CD21 (Dako, 1F8, 1:25), CD23 (Dako, MHM-6, prediluted), CD35 (Dako, Ber-MAC-DRC, 1:25), CD43 (Dako, DF-T1, prediluted), CD45 (Dako, LCA, 1:100), CD45RO (Dako, UCHL-1, 1:100), CD56 (Novocastra, NCL-CD56-1B6, 1:100,), CD79&#x3B1; (Dako, JCB117, 1:200), bcl-2 (Dako, 124, 1:150), cyclin D1 (Dako, DCS-6), TdT (Dako, A3524, 1:100), IgA (Dako, 6E2C1, 1:100), IgG (Dako, A57H, 1:150), IgM (Dako, polyclonal, 1:50), &#x3BA;-chain (Dako, polyclonal, 1:200), &#x3BB;-chain (Dako, polyclonal, 1:100), and Ki-67 (MBL Japan, MIB-1, 1:200)</p>
      <p>Immunohistochemically, the tumor cells were positive for CD5 (Figure <xref ref-type="fig" rid="F2">2A</xref>), CD20 (Figure <xref ref-type="fig" rid="F2">2B</xref>), CD43, CD45, CD79&#x3B1;, bcl-2, and &#x3BA;-chain (Figure <xref ref-type="fig" rid="F2">2C</xref>), but negative for &#x3BB;-chain (Figure <xref ref-type="fig" rid="F2">2D</xref>), CD2, CD3 (Figure <xref ref-type="fig" rid="F2">2E</xref>), CD10, CD21, CD23, CD35, CD45RO, CD56, TdT, IgA, IgG, IgM, IgD, and cyclin D1. The Ki-67 labeling was 10%. CD3-positive and CD45RO-positive inflammatory T-cells were scattered in a small amount. Light chains immunostainings showed light chain restriction (Figures <xref ref-type="fig" rid="F2">2C</xref> and <xref ref-type="fig" rid="F2">2D</xref>) and a small number of plasma cells (Figure <xref ref-type="fig" rid="F2">2C</xref>). Methylgreenpyronine staining showed a small number of plasma cells. The pathological diagnosis was CD5-positive MALT lymphoma. After the TBLB, a bone marrow biopsy was performed. It showed normocellular marrow with normal erythroid, granulocytoid and megakaryocytic maturation. No atypical cells were identified in the bone marrow.</p>
      <fig id="F2" position="float">
        <label>Figure 2</label>
        <caption>
          <p><bold>Immunohistochemical features</bold>. The tumor cells are positive for CD5 (A), CD20 (B), and &#x3BA;-chain (C). &#x3BB;-chain was negative (D). A, B, C: &#xD7;200. D, x400. The tumor cells were negative for CD3 (E). A small amount of CD3-positive inflammatory cells are seen (E). E: &#xD7;200.</p>
        </caption>
        <graphic xlink:href="1746-1596-7-16-2"/>
      </fig>
      <p>The patient rejected surgical procedure because of very old age, and was treated with chemotherapy (CHOP: cyclophosphamide, hydroxydaunorbicin, vincristine, and predonisone), and the lung tumor disappeared. The patient is now free of MALT lymphoma 10 years after the first manifestation.</p>
    </sec>
    <sec>
      <title>Discussion</title>
      <p>The present lung tumor was composed of B cells. The lymphoid cells were small. Plasma cell differentiation was seen in a slight degree. Lymphoepithelial lesions were scattered. &#x3BA;-chain was positive but &#x3BB;-chain was negative, confirming the light chain restriction and a tumor cell monoclonality. Therefore, the present case was low-grade B-cell lymphoma. The low grade and intermediate grade B-cell lymphoma consists of small lymphocytic lymphoma (low grade), lymphoplasmcytic lymphoma (low grade), follicular lymphoma (low grade), MALT lymphoma (low grade), and mantle cell lymphoma (intermediate grade). The present case is not small lymphocytic lymphoma/chronic leukocytic leukemia, which shows monotonous proliferation of mature small lymphocytes and free from centrocyte-like cells and lymphoepithelal lesions. Immunohistochemically, small lymphocytic lymphoma expresses IgM/IgD, CD20, CD22, CD5, CD19, CD79a, CD23, CD43 and CD11c. CD10 is negative. In the present case, IgM/D and CD23 were negative, supporting that the current case is not small lymphocytic lymphoma. The current case is not lymphoplasmacytic lymphoma because the plasma cells were scant in number and there was no M-protein. Negative immunoglobulins except for &#x3BA;-chain in tumor cells are also against the diagnosis of lymphoplasmacytic lymphoma. The presence of centrocyte-like cells, lymphoepithelial lesions, and plasmacytoid differentiation is characteristic features of MALT lymphoma. The clinical features are also against lymphoplasmacytic lymphoma, which frequently shows extrapulmonary and marrow involvements and shows M-protein and hyper-gamma-globulinemia. Positive &#x3BA;-chain in the current case may be due to the plasmacytoid differentiation of MALT lymphoma. The plasma cells in the present case are due to plasmacytoid differentiation of the MALT lymphoma, which is a characteristic feature of MALT lymphoma [<xref ref-type="bibr" rid="B2">2</xref>]. The present tumor is not follicular lymphoma because no follicular structures were recognized. The positive reaction for CD5 and negative reaction for CD10 and CD35 also exclude the possibility of follicular lymphoma, in which CD5 is negative and CD10 and CD35 (a marker of follicular dendritic cells) are positive. Although CD10 is infrequently positive in follicular lymphoma, the morphology, immunohistochemistry, the presence of plasmacytoid cells and lymphoepithelial lesions are in favor of MALT lymphoma rather than follicular lymphoma. The present tumor is not mantle cell lymphoma, because of negative cyclin D1 which is almost always positive in mantle cell lymphoma [<xref ref-type="bibr" rid="B17">17</xref>]. The differential diagnosis of CD5-positive MALT lymphoma and cyclin D1-negative mantle cell lymphoma is very difficult. Mantle cell lymphoma is composed of monotonous proliferation of small cells of mantle zone. In mantle cell lymphoma, no centrocyte-like cells, plasma cell differentiation, or lymphoepithelial lesions are seen. In the present case, the histologies are those of MALT lymphoma. In addition, the good prognosis of the present case is in favor of MALT lymphoma rather than mantle cell lymphoma, which shows poor prognosis. Therefore, the author diagnosed this tumor as MALT lymphoma. A genetic study of t(11:18)(q21:q21) (MALT lymphoma) and t(11:14)(q13:q31)(mantle cell lymphoma) are required for the distinction. In the present case, no genetic study was performed. The present case is different from benign lymphoproliferative diseases of lung, such as follicular bronchiolitis, lymphocytic interstitial pneumonia, and nodular lymphoid hyperplasia [<xref ref-type="bibr" rid="B18">18</xref>] because the present case shows neoplastic characteristics which were demonstrated by B-cell monoclonality and light chain restriction (light chain monoclonality). Thus, the neoplastic characteristics of the present case rule out these reactive lymphoproliferative conditions [<xref ref-type="bibr" rid="B18">18</xref>]. These findings are compatible with a diagnosis of MALT lymphoma of the lung.</p>
      <p>Immunohistochemically, the low and intermediate grade B-cell lymphomas show the following immunophenotypes: follicular lymphoma, CD5-, CD10 +, CD23 -, CD43 -, cyclin D1 -; MALT lymphoma, CD5-, CD10-, CD23-, CD43+/-, cyclin D1 -; mantle cell lymphoma, CD5+, CD10-, CD23-, CD43 +/-, cyclin D1 + [<xref ref-type="bibr" rid="B2">2</xref>]. The present case was as follows: CD5+, CD10-, CD43+, cyclin D1 -. The immunoprofile is compatible with to MALT lymphoma. The histological features of the present case, such as lymphoepithelial lesions and plasma cell differentiation, are also those of MALT lymphoma [<xref ref-type="bibr" rid="B2">2</xref>].</p>
      <p>The CD5 positivity of the present MALT lymphoma is unique. CD5-positive MALT lymphoma has been rarely reported [<xref ref-type="bibr" rid="B3">3</xref>-<xref ref-type="bibr" rid="B13">13</xref>]. The brief clinicopathological findings of the present case and reported cases are summarized in Table <xref ref-type="table" rid="T1">1</xref>. Ballesteros et al [<xref ref-type="bibr" rid="B3">3</xref>] mentioned that CD5-positive MALT lymphoma tended to show wide spread disease in the literature, and presented three cases of CD5-positive MALT lymphoma and stated that CD5-positive MALT lymphomas were localized tumors. The sites of the lymphoma were uterus, lymph nodes, lung, and conjunctiva [<xref ref-type="bibr" rid="B3">3</xref>]. Tasaki et al [<xref ref-type="bibr" rid="B4">4</xref>] reported two cases of CD5-positive MALT lymphoma of ocular adnexa. They stressed the differential diagnosis between CD5-positive MALT lymphoma and mantle cell lymphoma [<xref ref-type="bibr" rid="B4">4</xref>]. Hisabe et al [<xref ref-type="bibr" rid="B5">5</xref>] reported a case of CD5-positive MALT lymphoma of the rectum which regressed after administration of antibiotics. Sundeen et al [<xref ref-type="bibr" rid="B6">6</xref>] mentioned 11 cases of CD5-positive B-cell small lymphocytic malignancies of various organs. Mikolaenko and Listinsky [<xref ref-type="bibr" rid="B7">7</xref>] reported a case of CD5-positive MALT lymphoma with systemic involvement and Waldenstrom syndrome. Ferry et al [<xref ref-type="bibr" rid="B8">8</xref>] reported 3 cases of CD5-positive MALT lymphoma of orbit and tongue with recurrence. Kubota et al [<xref ref-type="bibr" rid="B9">9</xref>] reported 3 case of CD5-positive MALT lymphoma of orbit with autoantibodies. Tsukamoto et al [<xref ref-type="bibr" rid="B10">10</xref>] reported a case of cutaneous CD5-positive MALT lymphoma resembling the plasma cell variant of Castleman's disease. Wenzel et al [<xref ref-type="bibr" rid="B11">11</xref>] reported a case of CD5-positive MALT lymphoma of the conjunctiva with early dissemination and aggressive clinical behavior. Batstone et al [<xref ref-type="bibr" rid="B12">12</xref>] reported a case of CD5-positive MALT lymphoma of the breast and lymph nodes with genetic analyses. Heuring et al [<xref ref-type="bibr" rid="B13">13</xref>] reported a case of conjunctival CD5-positive MALT lymphoma. Because the number of cases of CD5-positive MALT lymphoma is very small, its biological characteristics are unknown.</p>
      <table-wrap id="T1" position="float">
        <label>Table 1</label>
        <caption>
          <p>The present case and reported cases of CD5-positive MALT lympoma</p>
        </caption>
        <table frame="hsides" rules="groups">
          <thead>
            <tr>
              <th align="left">Case</th>
              <th align="left">Age</th>
              <th align="left">Sex</th>
              <th align="left">Site</th>
              <th align="left">Morphology</th>
              <th align="left">LEL</th>
              <th align="left">Immunophenotype</th>
              <th align="left">Reporters</th>
              <th align="left"><bold>Ref</bold>.</th>
            </tr>
            <tr>
              <th align="left">No.</th>
              <th align="left">(yr)</th>
              <th/>
              <th/>
              <th/>
              <th/>
              <th/>
              <th/>
              <th/>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td align="left">1</td>
              <td align="left">72</td>
              <td align="left">F</td>
              <td align="left">Uterus</td>
              <td align="left">MALT</td>
              <td align="left">+</td>
              <td align="left">CD3 -, CD5 +, CD20 +</td>
              <td align="left">Ballesteros et al</td>
              <td align="left">[<xref ref-type="bibr" rid="B3">3</xref>]</td>
            </tr>
            <tr>
              <td align="left">1</td>
              <td align="left">72</td>
              <td align="left">F</td>
              <td align="left">Lymph nodes</td>
              <td align="left">MALT</td>
              <td align="left">+</td>
              <td align="left">CD3 -, CD5 +, CD10 -, CD11c +, CD20+, CD23 -</td>
              <td align="left">Ballesteros et al</td>
              <td align="left">[<xref ref-type="bibr" rid="B3">3</xref>]</td>
            </tr>
            <tr>
              <td align="left">2</td>
              <td align="left">56</td>
              <td align="left">M</td>
              <td align="left">Lung</td>
              <td align="left">MALT</td>
              <td align="left">+</td>
              <td align="left">CD3-, CD5 +, CD10+, CD20+,</td>
              <td align="left">Ballestetos et al</td>
              <td align="left">[<xref ref-type="bibr" rid="B3">3</xref>]</td>
            </tr>
            <tr>
              <td align="left">3</td>
              <td align="left">70</td>
              <td align="left">F</td>
              <td align="left">Conjunctive</td>
              <td align="left">MALT</td>
              <td align="left">+</td>
              <td align="left">CD3-, CD5+, CD10-, CD11c-, CD20 +</td>
              <td align="left">Ballestetos et al</td>
              <td align="left">[<xref ref-type="bibr" rid="B3">3</xref>]</td>
            </tr>
            <tr>
              <td align="left">4</td>
              <td align="left">57</td>
              <td align="left">F</td>
              <td align="left">Eyelid</td>
              <td align="left">MALT</td>
              <td align="left">+</td>
              <td align="left">CD3-, CD5+, CD10-, CD20+, CD23 - CD79&#x3B1;+, cyclin D1-, bcl-2+</td>
              <td align="left">Tasaki et al</td>
              <td align="left">[<xref ref-type="bibr" rid="B4">4</xref>]</td>
            </tr>
            <tr>
              <td align="left">5</td>
              <td align="left">67</td>
              <td align="left">M</td>
              <td align="left">Orbit</td>
              <td align="left">MALT</td>
              <td align="left">-</td>
              <td align="left">CD3-, CD5+, CD10-, CD20+, CD23 - CD79&#x3B1;+, cyclin D1-, bcl-2+, &#x3BA;chain+</td>
              <td align="left">Tasaki et al</td>
              <td align="left">[<xref ref-type="bibr" rid="B4">4</xref>]</td>
            </tr>
            <tr>
              <td align="left">6</td>
              <td align="left">70</td>
              <td align="left">F</td>
              <td align="left">Rectum</td>
              <td align="left">MALT</td>
              <td align="left">ND</td>
              <td align="left">CD5+, CD10-, CD20+, CD45RO-, bcl-2+</td>
              <td align="left">Hisabe et al</td>
              <td align="left">[<xref ref-type="bibr" rid="B5">5</xref>]</td>
            </tr>
            <tr>
              <td align="left">7</td>
              <td align="left">75</td>
              <td align="left">M</td>
              <td align="left">Systemic</td>
              <td align="left">MALT</td>
              <td align="left">+</td>
              <td align="left">CD5+, CD10-, CD19+, CD20+, CD11C-FMC7+, IgM&#x3BB;+</td>
              <td align="left">Mikolaenko et al</td>
              <td align="left">[<xref ref-type="bibr" rid="B7">7</xref>]</td>
            </tr>
            <tr>
              <td align="left">8</td>
              <td align="left">77</td>
              <td align="left">M</td>
              <td align="left">Orbit</td>
              <td align="left">MALT</td>
              <td align="left">+</td>
              <td align="left">CD5+, CD10-, CD20+, CD22 +CD23-, CD43-, IgM&#x3BB;+, Cyclin D1-, leu7 +</td>
              <td align="left">Ferry et al</td>
              <td align="left">[<xref ref-type="bibr" rid="B8">8</xref>]</td>
            </tr>
            <tr>
              <td align="left">9</td>
              <td align="left">44</td>
              <td align="left">M</td>
              <td align="left">Orbit, blood Marrow, lymph nodes</td>
              <td align="left">MALT</td>
              <td align="left">+</td>
              <td align="left">CD5+, CD10-, CD20 + CD22+, CD23-, CD43+, IgM&#x3BA;+, leu8+, cyclin D1-</td>
              <td align="left">Ferry et al</td>
              <td align="left">[<xref ref-type="bibr" rid="B8">8</xref>]</td>
            </tr>
            <tr>
              <td align="left">10</td>
              <td align="left">62</td>
              <td align="left">F</td>
              <td align="left">Tongue</td>
              <td align="left">MALT</td>
              <td align="left">+</td>
              <td align="left">CD5+, CD10-, CD20+, CD23+, CD43+sIg-, cyclin D1-</td>
              <td align="left">Ferry et al</td>
              <td align="left">[<xref ref-type="bibr" rid="B8">8</xref>]</td>
            </tr>
            <tr>
              <td align="left">11</td>
              <td align="left">82</td>
              <td align="left">ND</td>
              <td align="left">Orbit</td>
              <td align="left">MALT</td>
              <td align="left">ND</td>
              <td align="left">CD3-, CD5+, CD20+, CD23-, cyclinD1-</td>
              <td align="left">Kubota et al</td>
              <td align="left">[<xref ref-type="bibr" rid="B9">9</xref>]</td>
            </tr>
            <tr>
              <td align="left">12</td>
              <td align="left">70</td>
              <td align="left">ND</td>
              <td align="left">Orbit</td>
              <td align="left">MALT</td>
              <td align="left">ND</td>
              <td align="left">CD3-, CD5+, CD20+, CD23-, cyclinD1-</td>
              <td align="left">Kubota et al</td>
              <td align="left">[<xref ref-type="bibr" rid="B9">9</xref>]</td>
            </tr>
            <tr>
              <td align="left">13</td>
              <td align="left">84</td>
              <td align="left">ND</td>
              <td align="left">Orbit</td>
              <td align="left">MALT</td>
              <td align="left">ND</td>
              <td align="left">CD3-, CD5+, CD20+, CD23-, cyclinD1-</td>
              <td align="left">Kubota et al</td>
              <td align="left">[<xref ref-type="bibr" rid="B9">9</xref>]</td>
            </tr>
            <tr>
              <td align="left">14</td>
              <td align="left">57</td>
              <td align="left">F</td>
              <td align="left">Skin</td>
              <td align="left">MALT</td>
              <td align="left">ND</td>
              <td align="left">CD3-, CD5+, CD10-, CD20+, CD21-, CD23-, CD43+, bcl-2+, BSAP+, IgG&#x3BA;+</td>
              <td align="left">Tsukamoto et al</td>
              <td align="left">[<xref ref-type="bibr" rid="B10">10</xref>]</td>
            </tr>
            <tr>
              <td align="left">15</td>
              <td align="left">73</td>
              <td align="left">M</td>
              <td align="left">Conjunctiva</td>
              <td align="left">MALT</td>
              <td align="left">ND</td>
              <td align="left">CD2-, CD3-, CD5+, CD10-, CD20+, CD23-, CD79&#x3B1;+, Cyclin D1-</td>
              <td align="left">Wenzel et al</td>
              <td align="left">[<xref ref-type="bibr" rid="B11">11</xref>]</td>
            </tr>
            <tr>
              <td align="left">16</td>
              <td align="left">87</td>
              <td align="left">F</td>
              <td align="left">breast Lymph nodes</td>
              <td align="left">MALT</td>
              <td align="left">+</td>
              <td align="left">CD3-, CD5+, CD10-, CD21-, CD23-, bcl-2+&#x3BA;chain-,&#x3BB;chain+, bcl-6-. cyclinD1-</td>
              <td align="left">Batstone et al</td>
              <td align="left">[<xref ref-type="bibr" rid="B12">12</xref>]</td>
            </tr>
            <tr>
              <td align="left">17</td>
              <td align="left">79</td>
              <td align="left">M</td>
              <td align="left">Conjunctiva</td>
              <td align="left">MALT</td>
              <td align="left">-</td>
              <td align="left">CD5+, CD20+, CD23-, CD30-,</td>
              <td align="left">Heuring et al</td>
              <td align="left">[<xref ref-type="bibr" rid="B13">13</xref>]</td>
            </tr>
            <tr>
              <td align="left">18</td>
              <td align="left">82</td>
              <td align="left">F</td>
              <td align="left">Lung</td>
              <td align="left">MALT</td>
              <td align="left">+</td>
              <td align="left">CD2-, CD3-, CD5+, CD10-, CD20+, CD23-, CD43+, CD45+, CD45RO-, CD56-, CD79&#x3B1;bcl-2+,&#x3BA;chain+,&#x3BB;chain-, IgA-, IgG-, IgM-, TdT-, cyclinD1-</td>
              <td align="left">Terada Present case</td>
              <td/>
            </tr>
          </tbody>
        </table>
        <table-wrap-foot>
          <p>ND: not described. LEL: Lymphoepithelial lesion.</p>
        </table-wrap-foot>
      </table-wrap>
      <p>The MALT lymphoma of the present case disappeared after CHOP chemotherapy, and has not recurred for 10 years. Surgical procedure was not done because the patient rejected the surgical operation. The prognosis of pulmonary MALT lymphoma is not worse. The five year survival is 84-94% [<xref ref-type="bibr" rid="B1">1</xref>]. Kurtin et al. [<xref ref-type="bibr" rid="B19">19</xref>] described that lymphoma-specific survival of pulmonary MALT lymphoma was 71.7% at 10 years. Borie et al [<xref ref-type="bibr" rid="B20">20</xref>] described that the 5 years survival was 90% and 10 years survival was 72% in pulmonary MALT lymphoma. The present patient is alive free from tumor 10 years after the CHOP medical treatment without surgical intervention.</p>
    </sec>
    <sec>
      <title>Consent</title>
      <p>Written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.</p>
    </sec>
    <sec>
      <title>Competing interests</title>
      <p>The authors declare that they have no competing interests.</p>
    </sec>
  </body>
  <back>
    <ref-list>
      <ref id="B1">
        <mixed-citation publication-type="book">
          <name>
            <surname>Nicolson</surname>
            <given-names>AG</given-names>
          </name>
          <name>
            <surname>Harris</surname>
            <given-names>NL</given-names>
          </name>
          <person-group person-group-type="editor">Travis WD, Brambilla E, Konrad Muller-Hermelink HK, Harris CC</person-group>
          <article-title>Marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT) type</article-title>
          <source>World Health Organization Classification of Tumours. Pathology and genetics of tumours of the lung, pleura, thymus and heart</source>
          <year>2004</year>
          <publisher-name>IARC Press, Lyon</publisher-name>
          <fpage>pp88</fpage>
          <lpage>90</lpage>
        </mixed-citation>
      </ref>
      <ref id="B2">
        <mixed-citation publication-type="book">
          <name>
            <surname>Isaacson</surname>
            <given-names>PG</given-names>
          </name>
          <name>
            <surname>Chott</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Nakanuma</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Muller-Hermelink</surname>
            <given-names>HK</given-names>
          </name>
          <name>
            <surname>Harris</surname>
            <given-names>NL</given-names>
          </name>
          <name>
            <surname>Swerdlow</surname>
            <given-names>SH</given-names>
          </name>
          <person-group person-group-type="editor">Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW</person-group>
          <article-title>Extranodal marginal lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma)</article-title>
          <source>World Health Organization Classification of tumour. Pathology and Genetics of tumors of haematopoietic and lymphoid system</source>
          <year>2008</year>
          <publisher-name>IARC Press, Lyon</publisher-name>
          <fpage>pp214</fpage>
          <lpage>217</lpage>
        </mixed-citation>
      </ref>
      <ref id="B3">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Ballesteros</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Osborne</surname>
            <given-names>BM</given-names>
          </name>
          <name>
            <surname>Matsushima</surname>
            <given-names>AY</given-names>
          </name>
          <article-title>CD5+ low-grade marginal zone B-cell lymphomas with localized presentation</article-title>
          <source>Am J Surg Pathol</source>
          <year>1998</year>
          <volume>22</volume>
          <fpage>201</fpage>
          <lpage>207</lpage>
          <pub-id pub-id-type="doi">10.1097/00000478-199802000-00008</pub-id>
          <pub-id pub-id-type="pmid">9500221</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B4">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Tasaki</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Shichishima</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Furuta</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Yoshida</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Nakamura</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Abe</surname>
            <given-names>M</given-names>
          </name>
          <article-title>CD5-positive mucosa-associated lymphoid tissue (MALT) lymphoma of ocular adnexal origin: usefulness of fluorescence in situ hydridization and distinction between mantle cell lymphoma and MALT lymphoma</article-title>
          <source>Pathol Int</source>
          <year>2007</year>
          <volume>57</volume>
          <fpage>101</fpage>
          <lpage>107</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1440-1827.2006.02063.x</pub-id>
          <pub-id pub-id-type="pmid">17300675</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B5">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Hisabe</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Imamura</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Fukukawa</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Tsuda</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Matsui</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Yao</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Kanda</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Oshima</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Kikuchi</surname>
            <given-names>M</given-names>
          </name>
          <article-title>Regression of CD5-positive and Helicobactor-negative mucosa-associated lymphoid tissue lymphoma of the rectum after administration of antibiotics: report of a case</article-title>
          <source>Dis Colon Rectum</source>
          <year>2002</year>
          <volume>45</volume>
          <fpage>1267</fpage>
          <lpage>1270</lpage>
          <pub-id pub-id-type="doi">10.1007/s10350-004-6404-9</pub-id>
          <pub-id pub-id-type="pmid">12352248</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B6">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Sundeen</surname>
            <given-names>JT</given-names>
          </name>
          <name>
            <surname>Longo</surname>
            <given-names>DL</given-names>
          </name>
          <name>
            <surname>Jaffe</surname>
            <given-names>ES</given-names>
          </name>
          <article-title>CD5 expression in B-cell small lymphocytic malignancies: correlations with clinical presentation and site of disease</article-title>
          <source>Am J Surg Pathol</source>
          <year>1992</year>
          <volume>16</volume>
          <fpage>130</fpage>
          <lpage>137</lpage>
          <pub-id pub-id-type="doi">10.1097/00000478-199202000-00005</pub-id>
          <pub-id pub-id-type="pmid">1370753</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B7">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Mikolaenko</surname>
            <given-names>I</given-names>
          </name>
          <name>
            <surname>Listinsky</surname>
            <given-names>CM</given-names>
          </name>
          <article-title>Systemic CD5+ MALT lymphoma: presentation with Waldenstrom syndrome</article-title>
          <source>Ann Diagn Pathol</source>
          <year>2009</year>
          <volume>13</volume>
          <fpage>272</fpage>
          <lpage>277</lpage>
          <pub-id pub-id-type="doi">10.1016/j.anndiagpath.2008.04.010</pub-id>
          <pub-id pub-id-type="pmid">19608087</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B8">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Ferry</surname>
            <given-names>JA</given-names>
          </name>
          <name>
            <surname>Yang</surname>
            <given-names>W</given-names>
          </name>
          <name>
            <surname>Zukerberg</surname>
            <given-names>LR</given-names>
          </name>
          <name>
            <surname>Wotherspoon</surname>
            <given-names>AC</given-names>
          </name>
          <name>
            <surname>Arnold</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Harris</surname>
            <given-names>N</given-names>
          </name>
          <article-title>CD5+ extranodal marginal zone B-cell (MALT) lymphoma: a low grade neoplasm with a propensity for marrow involvement and relapse</article-title>
          <source>Am J Clin Pathol</source>
          <year>1996</year>
          <volume>105</volume>
          <fpage>31</fpage>
          <lpage>37</lpage>
          <pub-id pub-id-type="pmid">8561085</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B9">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Kubota</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Moritani</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Yoshino</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Nagai</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Terasaki</surname>
            <given-names>H</given-names>
          </name>
          <article-title>Correlation of autoantibodies and CD5+ B cells in ocular adnexal marginal zone B-cell lymphomas</article-title>
          <source>J Clin Pathol</source>
          <year>2010</year>
          <volume>63</volume>
          <fpage>79</fpage>
          <lpage>82</lpage>
          <pub-id pub-id-type="doi">10.1136/jcp.2009.067603</pub-id>
          <pub-id pub-id-type="pmid">20026703</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B10">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Tsukamoto</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Kojima</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Uchiyama</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Takeuchi</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Karasawa</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Murakami</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Sato</surname>
            <given-names>S</given-names>
          </name>
          <article-title>Primary cutaneous CD5+ marginal zone B-cell lymphoma resembling the plasm cell variant of Castleman's disease</article-title>
          <source>APMIS</source>
          <year>2007</year>
          <volume>115</volume>
          <fpage>1426</fpage>
          <lpage>1431</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1600-0463.2007.00797.x</pub-id>
          <pub-id pub-id-type="pmid">18184415</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B11">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Wenzel</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Diekmann</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Fiebiger</surname>
            <given-names>W</given-names>
          </name>
          <name>
            <surname>Mannhalter</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Chott</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Raderer</surname>
            <given-names>M</given-names>
          </name>
          <article-title>CD5 expression in a lymphoma of the mucosa-associated lymphoid tissue (MALT)-type as a marker for early dissemination and aggressive clinical behaviour</article-title>
          <source>Leukemia Lymphoma</source>
          <year>2001</year>
          <volume>42</volume>
          <fpage>823</fpage>
          <lpage>829</lpage>
          <pub-id pub-id-type="doi">10.3109/10428190109099348</pub-id>
          <pub-id pub-id-type="pmid">11697516</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B12">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Batstone</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Forsyth</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Goodlad</surname>
            <given-names>JR</given-names>
          </name>
          <article-title>Cytogenetic evidence for the origin of neoplastic cells in CD5-positive marginal zone B-cell lymphoma</article-title>
          <source>Hum Pathol</source>
          <year>2003</year>
          <volume>34</volume>
          <fpage>1065</fpage>
          <lpage>1067</lpage>
          <pub-id pub-id-type="doi">10.1053/S0046-8177(03)00400-3</pub-id>
          <pub-id pub-id-type="pmid">14608544</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B13">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Heuring</surname>
            <given-names>AH</given-names>
          </name>
          <name>
            <surname>Franke</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Hutz</surname>
            <given-names>W</given-names>
          </name>
          <article-title>Conjunctival CD5+ MALT lymphoma</article-title>
          <source>Br J Ophthalmol</source>
          <year>2001</year>
          <volume>85</volume>
          <fpage>498</fpage>
          <lpage>499</lpage>
          <pub-id pub-id-type="pmid">11302130</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B14">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Terada</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Kawaguchi</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Furukawa</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Sekido</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Osamura</surname>
            <given-names>Y</given-names>
          </name>
          <article-title>Minute mixed ductal-endocrine carcinoma of the pancreas with predominant intraductal growth</article-title>
          <source>Pathol Int</source>
          <year>2002</year>
          <volume>52</volume>
          <fpage>740</fpage>
          <lpage>746</lpage>
          <pub-id pub-id-type="doi">10.1046/j.1440-1827.2002.01416.x</pub-id>
          <pub-id pub-id-type="pmid">12685552</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B15">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Terada</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Kawaguchi</surname>
            <given-names>M</given-names>
          </name>
          <article-title>Primary clear cell adenocarcinoma of the peritoneum</article-title>
          <source>Tohoku J Exp Med</source>
          <year>2005</year>
          <volume>206</volume>
          <fpage>271</fpage>
          <lpage>275</lpage>
          <pub-id pub-id-type="doi">10.1620/tjem.206.271</pub-id>
          <pub-id pub-id-type="pmid">15942157</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B16">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Terada</surname>
            <given-names>T</given-names>
          </name>
          <article-title>Ductal adenoma of the breast: Immunohistochemistry of two cases</article-title>
          <source>Pathol Int</source>
          <year>2008</year>
          <volume>58</volume>
          <fpage>801</fpage>
          <lpage>805</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1440-1827.2008.02315.x</pub-id>
          <pub-id pub-id-type="pmid">19067857</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B17">
        <mixed-citation publication-type="book">
          <name>
            <surname>Swerdlow</surname>
            <given-names>SH</given-names>
          </name>
          <name>
            <surname>Campo</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Seto</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Muller-Hermelink</surname>
          </name>
          <person-group person-group-type="editor">Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW</person-group>
          <article-title>Mantle cell lymphoma</article-title>
          <source>World Health Organization Classification of tumour. Pathology and Genetics of tumors of haematopoietic and lymphoid system</source>
          <year>2008</year>
          <publisher-name>IARC Press, Lyon</publisher-name>
          <fpage>pp229</fpage>
          <lpage>232</lpage>
        </mixed-citation>
      </ref>
      <ref id="B18">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Travis</surname>
            <given-names>WD</given-names>
          </name>
          <name>
            <surname>Galvin</surname>
            <given-names>JR</given-names>
          </name>
          <article-title>Non-neoplastic pulmonary lymphoid lesions</article-title>
          <source>Thorax</source>
          <year>2001</year>
          <volume>56</volume>
          <fpage>964</fpage>
          <lpage>971</lpage>
          <pub-id pub-id-type="doi">10.1136/thorax.56.12.964</pub-id>
          <pub-id pub-id-type="pmid">11713361</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B19">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Kurtin</surname>
            <given-names>PJ</given-names>
          </name>
          <name>
            <surname>Myers</surname>
            <given-names>JL</given-names>
          </name>
          <name>
            <surname>Adlakha</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Strickler</surname>
            <given-names>JG</given-names>
          </name>
          <name>
            <surname>Lohse</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Pankratz</surname>
            <given-names>VS</given-names>
          </name>
          <name>
            <surname>Inwards</surname>
            <given-names>DJ</given-names>
          </name>
          <article-title>Pathologic and clinical features of primary pulmonary extranodal marginal zone B-cell lymphoma of MALT type</article-title>
          <source>Am J Surg Pathol</source>
          <year>2001</year>
          <volume>25</volume>
          <fpage>997</fpage>
          <lpage>1008</lpage>
          <pub-id pub-id-type="doi">10.1097/00000478-200108000-00003</pub-id>
          <pub-id pub-id-type="pmid">11474283</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B20">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Borie</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Wilslez</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Thalbut</surname>
            <given-names>G</given-names>
          </name>
          <etal/>
          <article-title>Clinical characteristics and prognostic factors of pulmonary MALT lymphoma</article-title>
          <source>Eur Respir J</source>
          <year>2009</year>
          <volume>34</volume>
          <fpage>1408</fpage>
          <lpage>1416</lpage>
          <pub-id pub-id-type="doi">10.1183/09031936.00039309</pub-id>
          <pub-id pub-id-type="pmid">19541720</pub-id>
        </mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
